Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Capital Leases: 2019-2025

Historic Capital Leases for Prestige Consumer Healthcare (PBH) over the last 6 years, with Sep 2025 value amounting to $19.3 million.

  • Prestige Consumer Healthcare's Capital Leases rose 15232.54% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 15232.54%. This contributed to the annual value of $20.6 million for FY2025, which is 11890.70% up from last year.
  • Latest data reveals that Prestige Consumer Healthcare reported Capital Leases of $19.3 million as of Q3 2025, which was down 3.29% from $20.0 million recorded in Q2 2025.
  • Prestige Consumer Healthcare's 5-year Capital Leases high stood at $20.6 million for Q1 2025, and its period low was $126,000 during Q3 2024.
  • Its 3-year average for Capital Leases is $6.1 million, with a median of $945,000 in 2023.
  • In the last 5 years, Prestige Consumer Healthcare's Capital Leases crashed by 92.95% in 2023 and then skyrocketed by 15,232.54% in 2025.
  • Quarterly analysis of 5 years shows Prestige Consumer Healthcare's Capital Leases stood at $4.8 million in 2021, then slumped by 50.61% to $2.4 million in 2022, then slumped by 91.82% to $195,000 in 2023, then surged by 1,990.77% to $4.1 million in 2024, then spiked by 15,232.54% to $19.3 million in 2025.
  • Its Capital Leases was $19.3 million in Q3 2025, compared to $20.0 million in Q2 2025 and $20.6 million in Q1 2025.